The Clinical Impact and Prognostic Value of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer: Real-world Evidence from a Monocentric, Prospective Observational Study

Description:

The investigators now intend to prospectively generate evidence-based data in everyday clinical practice with this so-called Real-World-Evidence (RWE) study. The planned study will enable us to analyze the diagnostic accuracy of Radelumin® in more detail under everyday conditions, whereby dedicated examinations of certain subgroups and the prospective generation of a complete, high-quality database for the future use of artificial intelligence (AI) will be made possible.

Sponsor:

Heinrich-Heine University

Contacts:

Eduards Mamlins (MD)

eduards.mamlins@med.uni-duesseldorf.de

(+49)211 8108069

Emil Novruzov (MD)

emil.novruzov@med.uni-duesseldorf.de

(+49)211 8118540

[18F] PSMA-1007

Isotope(s):
Target(s):
  • PSMA
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468